@article{cc03bf23e79c4ce495422c126415c422,
title = "Photoprotection for skin of all color: Consensus and clinical guidance from an expert panel",
abstract = "The negative effects of sun exposure have become better accepted among health care professionals and the lay public over recent decades. Most attention has been focused on the effects of UV light, particularly UVB wavelengths (290-320 nm). Accordingly, products to protect skin from sunlight-associated harm (sunscreens) have been developed to minimize UVB exposure. The effects of longer wavelengths, including UVA (320-400 nm) and visible light (VL, 400-700 nm), are increasingly appreciated. VL accounts for approximately half of the solar radiation that reaches the earth's surface and understanding of its effects on the skin is improving. Studies have shown that VL can induce hyperpigmentation in individuals with dark skin types (Fitzpatrick skin types IV-VI). In addition, VL can contribute to the exacerbation of pigmentary disorders, including melasma. Because these findings are relatively new, there are gaps in understanding the needs for photoprotection and guidance for clinicians. A panel of dermatologists and photobiologists was convened to develop consensus recommendations and clinical guidance about sunscreen use relevant to the current understanding of risks associated with sun exposure using a modified Delphi method.",
keywords = "photoprotection, skin of color, sunscreens, ultraviolet light, visible light",
author = "Rigel, {Darrell S.} and Taylor, {Susan C.} and Lim, {Henry W.} and Alexis, {Andrew F.} and Armstrong, {April W.} and {Chiesa Fuxench}, {Zelma C.} and Draelos, {Zoe D.} and Hamzavi, {Iltefat H.}",
note = "Funding Information: Funding sources: This article is published as part of a supplement sponsored by Beiersdorf Inc. Supported by an unrestricted educational grant from Beiersdorf. Authors received honoraria. Funding Information: Dr Taylor has served as an investigator for Concert Pharmaceuticals, Croma-Pharma GmbH, Eli Lilly and Company, Immune Tolerance Network, and Pfizer; as a consultant/speaker/advisory board member for AbbVie, Arcutis Biotherapeutics, Beiersdorf Inc, Biorez, Inc, CannTec, Evolus, Galderma Laboratories, GloGetter Inc, L'Oreal USA, Inc, LuminDX, Medscape/WebMD, Johnson & Johnson Consumer Products, Scientis, and Vichy Laboratories; and has received book royalties from McGraw Hill. Dr Lim has served as investigator (grant to institution) for Incyte, L'Oreal, Pfizer, and Patient-Centered Outcomes Research Institute; as a consultant for Pierre Fabre, ISDIN, Ferndale, La Roche-Posay, and Beiersdorf; and as a speaker in a general education session for La Roche-Posay and Cantabria Labs. Dr Alexis has received grant/research support from Leo Pharma, Novartis, Almirall, Bristol Myers Squibb, Amgen, Menlo, Galderma, Valeant (Bausch Health), Cara, and Arcutis Biotherapeutics; and has served as a consultant/speaker for Leo Pharma, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Valeant, L'Oreal, Bristol Myers Squibb, Bausch Health, UCB Pharma, Vyne Therapeutics, Arcutis Biotherapeutics, Janssen, Allergan, Almirall, AbbVie, Sol-Gel, Amgen, Regeneron, Sanofi-Genzyme, Pfizer, and AstraZeneca. Dr Armstrong has served as research investigator and/or scientific advisor to AbbVie, ASLAN, Boehringer Ingelheim, Bristol Myers Squibb, EPI, Incyte, Leo Pharma, UCB Pharma, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira Inc, Sanofi, Regeneron, Pfizer, and Modmed. Dr Chiesa Fuxench has served as a consultant for the Asthma and Allergy Foundation of America and the National Eczema Association, Pfizer, Incyte and AbbVie for which she received honoraria for work related to atopic dermatitis; served as consultant for Beiersdorf, which supported this work, has received research grants from Regeneron, Sanofi, Tioga, Vanda, Menlo Therapeutics, Leo Pharma, and Eli Lilly for work related to atopic dermatitis; and has received honoraria for continuing medical education work in atopic dermatitis sponsored by educational grants from Regeneron and Sanofi. Dr Draelos has served as a consultant for Beiersdorf. Dr Hamzavi has served as an investigator (grant to institution) for Pfizer Inc, Bayer, Lenicura, and Incyte, Estee Lauder, L'Oreal, Unigen, Avita, Arcutis Biotherapeutics, and Ferndale Laboratories, Inc; as an Advisory Board member for AbbVie; and as a Consultant to Galderma Laboratories, LP, Incyte, Pfizer, UCB, Boehringer Ingelheim, Beiersdorf, and Clarify Medical. Dr Rigel has served as an advisor/consultant for Almirall, Beiersdorf, Castle Biosciences, Inc, DermTech, Ferndale, Johnson & Johnson, Myriad Genetics, Ortho Dermatologics, Pfizer, and Scibase. Evince Communications has served as scientific consultants for Beiersdorf, Inc, on educational initiatives and the dermMentors Resident of Distinction Award Program.The authors thank Rene Alvarez, PhD and Valerie Sanders from Evince Communications for providing editorial support including development of the rough draft of the manuscript based exclusively on the results of the modified Delphi questionnaires, group discussions, and input from the corresponding authors. This assistance was funded via unrestricted educational funding from Beiersdorf, Inc, which supported this work. The final version solely represents the views of the authors and was approved by each author prior to submission. Publisher Copyright: {\textcopyright} 2021 American Academy of Dermatology, Inc.",
year = "2022",
month = mar,
doi = "10.1016/j.jaad.2021.12.019",
language = "English",
volume = "86",
pages = "S1--S8",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",
}